Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401272 | 1.00 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL14584328 | 0.90 | FOLH1 (0.51) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL2030857 | 0.90 | FOLH1 (0.51) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL29641557 | 0.90 | FOLH1 (0.51) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL29398014 | 0.90 | FOLH1 (0.51) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL24489613 | 0.90 | FOLH1 (0.51) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL3962011 | 0.87 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL31260547 | 0.87 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL21192398 | 0.87 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL31370328 | 0.87 | MDM2 (0.51) | MDM4TP53CASP3MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| US-20150297761-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-10-22 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| WO-2014075079-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1379874-A1 | PHYCOERYTHRIN LABELED THYRONINE ANALOGUES AND ASSAYS USING THE LABELED ANALOGUES | BIO-RAD LABORATORIES, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030125257-A1 | Assay for identifying beta secretase inhibitors | HOFFMANN-LA ROCHE INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002073202-A1 | PHYCOERYTHRIN LABELED THYRONINE ANALOGUES AND ASSAYS USING THE LABELED ANALOGUES | BIO-RAD LABORATORIES, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6423549-B1 | COMPETITIVE BINDING; IMMUNOASSAY; FLUORESCENT; MEDICAL DIAGNOSIS | BIO-RAD LABORATORIES, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| EP-0728469-A2 | An endermic liniment | SHISEIDO COMPANY LIMITED (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0438873-A1 | Inhibitor of ribonucleotide reductase of herpes viruses | MERCK & CO. INC. (US) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | MDM4 1166/4885TP53 1635/4885CASP3 2910/4885 |
| US-20150297761-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | ARGLU1, CA1, SSTR3 | MDM4 1751/4885TP53 4159/4885CASP3 3790/4885 |
| US-20030125257-A1 | Assay for identifying beta secretase inhibitors | BACE1, BACE2, APP | MDM4 2701/4885TP53 1435/4885CASP3 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.